Oxford vaccine, looking very good

Oxford / AstraZeneca

Phase 2 / 3

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext

(23rd November)

https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html

Viral vector, weakened version, chimpanzee, common cold adenovirus

After vaccination, the surface spike protein is produced

Antibodies

T cells
Interim report, 131 confirmed infections
Positive high-level results
8,000 swabs per week
Therefore picking up asymptomatics
Clinical trials of AZD1222
UK and Brazil data only
Vaccine was highly effective in preventing COVID-19
No hospitalisations or severe cases of the disease were reported in participants receiving the vaccine
Group one, n = 2,741
AZD1222 was given as a half dose
Followed by a full dose
At least one month apart
Vaccine efficacy of 90%
Group 2, n = 8,895
Two full doses at least one month apart
Vaccine efficacy 62 %
Combined analysis from both dosing regimens, n = 11,636
An average efficacy of 70%
All results were statistically significant (p less than = 0.0001)
One in 10,000
More data will continue to accumulate
Refining the efficacy reading
Establishing the duration of protection.
Independent Data Safety Monitoring Board
Met its primary endpoint
Protection from COVID-19 occurring 14 days or more after receiving two doses
No serious safety events related to the vaccine have been confirmed
AZD1222 was well tolerated across both dosing regimens
AstraZeneca immediately prepare regulatory submission
Early approval
Emergency Use Listing from the World Health Organization
For an accelerated pathway to low-income countries
Full analysis of the interim results is being submitted for peer-reviewed journal
Professor Andrew Pollard
These findings show that we have an effective vaccine that will save many lives
Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used,
more people could be vaccinated with planned vaccine supply
..